Monoclonal anti-GT 468 antibodies for treatment of cancer
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.
1. A method of inhibiting growth of a human cancer cell expressing GT468, comprising contacting the cell with an anti-GT468 antibody selected from the group consisting of:
(i) an antibody fragment comprising six complementarity determining regions (CDRs) of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042,
(ii) a chimerized or humanized antibody comprising six CDRs of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042,
(iii) a full-length antibody comprising six CDRs of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042, and
(iv) an antibody of (i), (ii), or (iii) coupled to a therapeutic agent;
wherein the cancer cell is selected from the group consisting of breast cancer, lung cancer, gastric cancer, ovarian cancer, colon cancer, pancreatic cancer, head & neck cancer, kidney cancer, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and metastatic forms of the aforementioned cancers.
2. A method of killing a human cancer cell expressing GT468, comprising contacting the cell with an effective amount of an anti-GT468 antibody selected from the group consisting of:
(i) an antibody fragment comprising six CDRs of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042,
(ii) a chimerized or humanized antibody comprising six CDRs of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042,
(iii) a full-length antibody comprising six CDRs of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042, and
(iv) an antibody of (i), (ii), or (iii) coupled to a therapeutic agent;
wherein the cancer cell is selected from the group consisting of breast cancer, lung cancer, gastric cancer, ovarian cancer, colon cancer, pancreatic cancer, head & neck cancer, kidney cancer, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and metastatic forms of the aforementioned cancers.
3. A method of inhibiting metastatic spread of a human cancer cell expressing GT468, comprising contacting the cell with an effective amount of an anti-GT468 antibody selected from the group consisting of:
(i) an antibody fragment comprising six CDRs of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042,
(ii) a chimerized or humanized antibody comprising six CDRs of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042,
(iii) a full-length antibody comprising six CDRs of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042, and
(iv) an antibody of (i), (ii), or (iii) coupled to a therapeutic agent;
wherein the cancer cell is selected from the group consisting of breast cancer, lung cancer, gastric cancer, ovarian cancer, colon cancer, pancreatic cancer, head & neck cancer, kidney cancer, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and metastatic forms of the aforementioned cancers.
4. A method of treating a human cancer characterized by cancer cells expressing GT468 in a subject, comprising administering to said subject an anti-GT468 antibody selected from the group consisting of:
(i) an antibody fragment comprising six CDRs of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042,
(ii) a chimerized or humanized antibody comprising six CDRs of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042,
(iii) a full-length antibody comprising six CDRs of an antibody produced by a hybridoma deposited under the accession number DSM ACC3039, DSM ACC3037, DSM ACC3036, DSM ACC3038, DSM ACC3040, or DSM ACC3042,
(iv) an antibody of (i), (ii), or (iii) coupled to a therapeutic agent, and
(v) a pharmaceutical composition comprising;
(1) an antibody of (i), (ii), (iii), or (iv); and
(2) a pharmaceutically acceptable carrier;
wherein the cancer is selected from the group consisting of breast cancer, lung cancer, gastric cancer, ovarian cancer, colon cancer, pancreatic cancer, head & neck cancer, kidney cancer, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and metastatic forms of the aforementioned cancers.
5. The method of any one of claims 1 to 4 , wherein the therapeutic agent is a toxin, a radioisotope, a drug, or a cytotoxic agent.